Phase 2 Stroke Trial, Recruiting NCT04789616 Sponsor: University of Calgary Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT04789616
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had an ischemic stroke (caused by a blockage) affecting the front part of one side of the brain
  • People who are 18 years of age or older
  • People who are at least 5 days past their stroke but no more than 8 weeks past their stroke when treatment starts
  • People who have weakness on one side of the body (arm and/or leg) that requires inpatient rehabilitation
  • People who have someone available to help with daily rehabilitation practice and transportation when needed
  • People who have enough language ability to understand the consent forms and follow daily therapy instructions
  • People who have at least some movement in the shoulder or fingers, OR some visible movement in the hip

Who may not be able to join:

  • People who had a significant disability or difficulty with daily activities before the stroke
  • People who do not have sufficient resources or whose health would prevent them from eventually returning to living outside of a care facility
  • People with a history of dementia
  • People with a history of hepatitis, or liver problems shown by abnormal liver test results
  • People with a history of kidney problems or poor kidney function based on blood test results
  • People with cancer or another serious ongoing illness that makes surviving one year unlikely, or that would interfere with exercise and skill practice
  • People who had a significant disabling condition before the stroke (for example, Parkinson's disease, severe brain injury, or amputation)
  • People who had a seizure related to their stroke
  • People with a current or past diagnosis of epilepsy
  • People currently taking any of the following seizure medications: Carbamazepine, Phenobarbital, or Phenytoin
  • People who are pregnant, breastfeeding, or who test positive for pregnancy at the start of the trial
  • Women who could become pregnant and are not using at least one highly effective form of birth control, or two forms of effective birth control
  • People who are known to be HIV positive
  • People currently taking any of the following antifungal or antibiotic medications: Ketoconazole, Itraconazole, Voriconazole, Rifampin, Clarithromycin, or Rifabutin combined with a Protease Inhibitor
  • People currently taking the herbal supplement St. John's Wort
  • People currently taking Paxlovid

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sean Dukelow, MD PhD FRCPC, University of Calgary

Phone: 403-944-4050

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
15 September 2022
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Fugl-Meyer Upper Extremity Assessment Score; Change in 10-Meter Walk Test Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov